Join the Oncology Voice Network. Join for Free
How to ENGAGE and work with MSL Recruiters, and WHY!
Medical Science Liaison MSL recruitment recruitment firms career growth industry conferences

How to ENGAGE and work with MSL Recruiters, and WHY!


Share This Article


Summary

In this episode, Tom Caravela welcomes Daniel Herr to delve into the intricacies of recruitment within the medical science liaison field. Daniel shares insights on the different types of recruitment firms and the advantages of collaborating with recruiters. He offers practical advice on how to find and engage effectively with recruiters, manage expectations, and maintain communication. The discussion also covers strategies for aspiring MSLs, including networking tips and the importance of industry conferences. Daniel emphasizes the value of preparation and relationship-building in interviews, concluding with valuable advice for career growth and expressing gratitude for the engaging conversation.

Daniel Herr, Director of Recruitment and Operations at The Carolan Group discusses how to ENGAGE and work with MSL recruitment firms and why you should consider them.

In this episode we discuss:

  • Daniel’s background
  • The role of an MSL recruiter and different types.
  • Why is it a good idea for a job seeker to work with a Recruiter or Recruiters?
  • How can a job seeker go about identifying the right recruiter for their search efforts?
  • Once they identify the Recruiters they want to work with, how do they go about engaging with them?
  • What can the job seeker expect and anticipate from the Recruiter
  • What does the Recruiter expect from the job seeker?
  • What if a Job Seeker does not hear back from or loses touch with a Recruiter
  • What if the job seeker gets far along in the process and the company starts dealing directly, how does the job seeker handle it? 
  • Will the Recruiter help in the job offer negotiations? What can Job Seekers do to ensure a successful relationship with a Recruiter?
  • How often should Job Seekers to stay in touch with the Recruiter

Click for Source
Medical Science Liaison, MSL recruitment, recruitment firms, career growth, industry conferences

Related Topics

Meet Our Innovation Partners

Loading partners...

You May Also Like

Podcast
Social Media Listening Evolved
Partner Avatar MSL Talk: Tom Caravela, Conor McGladrigan, Kevin Peterson

Social Media Listening Evolved

Podcast
Over-Negotiation-How to Botch a Job Offer
Partner Avatar MSL Talk: Tom Caravela

Over-Negotiation-How to Botch a Job Offer

Article
Confounding factors in exposure–response analyses and mitigation strategies for monoclonal antibodies in oncology
OVN Avatar Sonoko Kawakatsu, René Bruno, Matts Kågedal, Chunze Li, Sandhya Girish, Amita Joshi, Benjamin Wu

Confounding factors in exposure–response analyses and mitigation strategies for monoclonal antibodies in oncology

Article
Level of evidence used in recommendations by the National Comprehensive Cancer Network (NCCN) guidelines beyond Food and Drug Administration approvals
OVN Avatar R. Kurzrock, L.A. Gurski, R.W. Carlson, D.S. Ettinger, S.M. Horwitz, S.K. Kumar, L. Million, M. von Mehren, A.B. Benson III

Level of evidence used in recommendations by the National Comprehensive Cancer Network (NCCN) guidelines beyond Food and Drug Administration approvals

Article
EHA evaluation of the ESMO-Magnitude of Clinical Benefit Scale version 1.1 (ESMO-MCBS v1.1) for hematological malignancies
OVN Avatar Barbara Kiesewetter , Nathan I Cherny, Nicolas Boissel, Francesco Cerisoli, Urania Dafni, Elisabeth G E de Vries, Paolo Ghia, Nicola Gökbuget, Verónica González-Calle, Brian Huntly, Ulrich Jäger, Nicola Jane Latino, Jean-Yves Douillard, Luca Malcovati, Ma

EHA evaluation of the ESMO-Magnitude of Clinical Benefit Scale version 1.1 (ESMO-MCBS v1.1) for hematological malignancies

Article
The First 2 Years of Biosimilar Epoetin for Cancer and Chemotherapy-Induced Anemia in the U.S.: A Review from the Southern Network on Adverse Reactions
OVN Avatar Charles L. Bennett , Sumimasa Nagai , Andrew C. Bennett , Shamia Hoque , Chadi Nabhan , Martin W. Schoen , William J. Hrushesky , Stefano Luminari , Paul Ray , Paul R. Yarnold , Bart Witherspoon , Josh Riente , Laura Bobolts , John Brusk , Rebecca Tombles

The First 2 Years of Biosimilar Epoetin for Cancer and Chemotherapy-Induced Anemia in the U.S.: A Review from the Southern Network on Adverse Reactions

Explore OVN